ArticleBMC women's health2025
Contrast-enhanced ultrasound findings of ovarian Sertoli-Leydig cell tumor: a case report with ultrasonographic-pathological insights.
Article in BMC women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundOvarian Sertoli-Leydig Cell Tumors (SLCTs) are exceedingly rare sex cord-stromal tumors with non-specific clinical features and limited diagnostic imaging. We evaluated the ultrasonographic-pathological correlation of ovarian SLCT and explored the clinical value of contrast-enhanced ultrasound (CEUS) through a case analysis of a 62-year-old woman with a SLCT. CASE PRESENTATION: A 62-year-old postmenopausal woman presented with abdominal distension. Serum testosterone was elevated (4.43 nmol/L; normal range 0.45-1.26nmol/L). Ultrasound revealed a large multilocular cystic lesion with solid components in the pelvic-abdominal region, marked by abundant blood flow within the septa and solid areas, along with low-resistance arterial flow in the solid component of the tumor. CEUS demonstrated rapid and heterogeneous high enhancement in the tumor's cystic wall, septa, and solid components during the wash-in phase. Additionally, there was early washout compared to the myometrial layer. Total hysterectomy with bilateral salpingo-oophorectomy was performed. Histopathology confirmed moderately-poorly differentiated SLCT.
conclusionsThe CEUS pattern of SLCT (rapid heterogeneous hyperenhancement with early wash-out) is similar to that of malignant ovarian tumors. The diagnosis of SLCT cannot rely solely on imaging findings. Integrated clinical and laboratory findings are crucial for differentiating SLCT from ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.